{"DataElement":{"publicId":"7848385","version":"1","preferredName":"Sequence Analysis Neoplasm Timepoint Other Specify","preferredDefinition":"A text description to specify another timepoint used for the tumor sequence analysis evaluation.","longName":"SEQ_TMR_ITP_TXT","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"7848383","version":"1","preferredName":"Sequence Analysis Neoplasm Timepoint","preferredDefinition":"The determination of the sequence of component residues in a macromolecule, e.g. amino acids in a protein or nucleotide bases in DNA/RNA or the computational analysis performed to determine the similarities between nonidentical proteins or molecules of DNA or RNA._A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias._A specific point in the time continuum, including those established relative to an event.","longName":"6999947v1.0:7848381v1.0","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"6999947","version":"1","preferredName":"Sequence Analysis","preferredDefinition":"The determination of the sequence of component residues in a macromolecule, e.g. amino acids in a protein or nucleotide bases in DNA/RNA or the computational analysis performed to determine the similarities between nonidentical proteins or molecules of DNA or RNA.","longName":"C17565","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sequence Analysis","conceptCode":"C17565","definition":"The determination of the sequence of component residues in a macromolecule, e.g. amino acids in a protein or nucleotide bases in DNA/RNA or the computational analysis performed to determine the similarities between nonidentical proteins or molecules of DNA or RNA.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"950C3F6F-DD76-7971-E053-F662850A58BC","latestVersionIndicator":"Yes","beginDate":"2019-10-16","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-10-16","modifiedBy":"ONEDATA","dateModified":"2019-10-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"7848381","version":"1","preferredName":"Neoplasm Timepoint","preferredDefinition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.:A specific point in the time continuum, including those established relative to an event.","longName":"C3262:C68568","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neoplasm","conceptCode":"C3262","definition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Timepoint","conceptCode":"C68568","definition":"A specific point in the time continuum, including those established relative to an event.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D26E6A89-73F6-1C5C-E053-4EBD850AD52A","latestVersionIndicator":"Yes","beginDate":"2021-12-05","endDate":null,"createdBy":"LAMEMIL","dateCreated":"2021-12-05","modifiedBy":"ONEDATA","dateModified":"2021-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008557","version":"1","preferredName":"Lab Results","preferredDefinition":"the results of laboratory tests.","longName":"LAB_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFBA7D-D009-7227-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D26E6A89-7407-1C5C-E053-4EBD850AD52A","latestVersionIndicator":"Yes","beginDate":"2021-12-05","endDate":null,"createdBy":"LAMEMIL","dateCreated":"2021-12-05","modifiedBy":"KUMMEROA","dateModified":"2022-02-03","changeDescription":"2022-2-3 ak Released.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2666713","version":"2","preferredName":"Other Specify","preferredDefinition":"Different than the one(s) previously specified or mentioned._Be specific about something; define clearly.","longName":"OTH_SPEC","context":"NCI Standards","contextVersion":"1","type":"Non-enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2208051","version":"1","preferredName":"Other Specify","preferredDefinition":"Not otherwise specified.:Specify; be specific about something; define clearly.","longName":"C17649:C25685","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Specify","conceptCode":"C25685","definition":"Be specific about something; define clearly.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-3B5E-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NCI CRF Standards","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"132D4785-528E-5337-E050-BB89AD433CA8","latestVersionIndicator":"Yes","beginDate":"2015-04-07","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2015-04-07","modifiedBy":"HARTLEYG","dateModified":"2018-06-06","changeDescription":"7/19/17 jk transferred context and added registration status, CSI per Round 5 finalization task. 4/28/15 released. jc  4/7/15 VD versioned per COG WG: inc to 100 char, remove min limit, chg concept domain to assessment result. jc 1/25/13 added ACRIN Old caBIG CSI.  3/21/12 - changed origin from IVI to ACRIN.  3/5/08 - released for UoWASH FES CRF.   7/23/07-created for ACRIN PET CDEs","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"COG","type":"USED_BY","context":"COG"}],"ReferenceDocuments":[{"name":"Specify other timepoint used","type":"Preferred Question Text","description":"Specify other timepoint used for the tumor sequence analysis evaluation:","url":null,"context":"COG"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"If Other, specify:","url":null,"context":"COG"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D26E6A89-741E-1C5C-E053-4EBD850AD52A","latestVersionIndicator":"Yes","beginDate":"2021-12-05","endDate":null,"createdBy":"LAMEMIL","dateCreated":"2021-12-05","modifiedBy":"KUMMEROA","dateModified":"2022-02-03","changeDescription":"2022-2-3 ak Released. Revised preferred question text LF 2/2/2022","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}